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The bactericidal efficacy of amikacin, isepamicin and netilmicin was studied against
Pseudomonas aeruginosa and Serratia marcescens over a treatment period of 30 h
using two one-compartment in-vitro models with differently designed culture
compartments. High bacterial inocula were exposed to fluctuating drug concentra-
tions, simulating human serum concentrations (tm - 2 h) during clinical treatment.
The same daily dose was administered as 1 h infusions given every 8 h or every 24 h,
resulting in peak concentrations of 8 and 24 mg/1 for netilmicin, and 24 and 72 mg/1
for amikacin and isepamicin, respectively. Once-daily dosing was more bactericidal
during initial treatment in the in-vitro models (P < 0-01) and at least as effective as
thrice-daily dosing in preventing bacterial regrowth, despite a prolonged period of
subinhibitory drug concentration before administration of the second dose. Lower
ratios of peak concentration to MIC were needed to achieve bactericidal activity
(> 99-9% reduction of cfu) after 24 h treatment against S. marcescens compared
with P. aeruginosa (/> < 0-01). All nine regimens providing peaks of at least four
times the MIC were bactericidal against S. marcescens after 24 h exposure. In
contrast, a bactericidal effect against P. aeruginosa occurred only during two of six
experiments with peaks of four to nine times the MIC. Similar results were obtained
in both in-vitro models of infection. These data suggest insufficient intrinsic activity
of the aminoglycosides studied for single drug treatment of P. aeruginosa in the
absence of host-defence mechanisms.
Introduction
Multiple daily dosing regimens of aminoglycosides have been used for more than three
decades to treat systemic bacterial infections. However, data from in-vitro and experi-
mental in-vivo studies suggest that once-daily dosing of aminoglycoside might be at
least as efficacious and potentially less toxic (Frame et al., 1977; Blaser, Stone &
Zinner, 1985a; Gerber et al., 1989; Mattie, Craig & Pechere, 1989). Single-daily dosing
of aminoglycosides has also been studied clinically (Powell et al., 1983; Hollender et al.,
1989). However, a large number of patients need to be evaluated in comparative studies
to detect clinically significant differences in either efficacy or toxicity.
Optimal dosing of antibiotics has been studied in various in-vitro models of infection
(Blaser & Zinner, 1987). In the present study cultures of Pseudomonas aeruginosa and
Serratia marcescens were treated with amikacin, netilmicin or isepamicin, simulating
human serum pharmacokinetics. Each drug was administered either once- or
thrice-daily.
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Methods
Antibacterial efficacy of isepamicin, amikacin and netilmicin was studied in two in-vitro
models of infection over treatment periods of 30 h. Figures 1 and 2 show schematic
drawings of the two one-compartment models (V and G), each with a differently
designed growth chamber. In model V the culture chamber consisted of a 10 ml
Vacutainer glass tube with siliconized glass walls. The cultures were not stirred and
direct contact with air was maintained. In model G bacteria were cultured in a 20 ml
glass and stainless steel compartment. The cultures were continuously stirred with a
magnetic stirrer. The culture medium was not in direct contact with air and only the
oxygen dissolved within the culture medium reservoir was pumped into the culture
chamber.
Cultures of three strains of P. aeruginosa (one laboratory reference strain, ATCC
27853, and two clinical isolates) were studied in both one-compartment models. In
addition, three clinical isolates of S. marcescens were exposed to the antibiotics in
model G. High bacterial inocula of 5 x 106/ml in a volume of 10 ml were exposed to
fluctuating drug concentrations, simulating human serum concentrations during treat-
ment. The elimination half-lives were defined according to the ratio of flow rate to
culture volume and adjusted to 2 h (Blaser & Zinner, 1987). For each drug the same
daily dose was administered as 1-h infusions given either every 24 h (q24 h) or every
8 h (q8 h). Amikacin and isepamicin doses were three times higher than netilmicin for
these experiments to account for the differences in dosing during clinical therapy.
Concentrations were measured with fluorescence polarization immunoassay (TDX,
Abbott). Peak concentrations for the q24 h and q8 h regimens were 24 and 8 mg/1 for
netilmicin, and 72 and 24 mg/1 for amikacin and isepamicin, respectively. For both
amikacin regimens measured and predicted concentrations are shown in Figure 3(a).
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Figure 1. Schematic drawing of a one-compartment model with a 10 ml Vacutainer tube as the growth
chamber (model V). The glass walls of the tube were treated with silicon. The culture medium was not stirred
and was in direct contact with air.
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Figure 2. Schematic drawing of a one-compartment model with a 20 ml glass and stainless steel culture
compartment (model G). The model excludes direct air contact within the culture compartment. The culture
is stirred continuously by a magnetic stirrer.
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Figure 3. Impact of dosage regimen of amikacin against P. aeruginosa 27853 in a one-compartment model
(model G). (a) Measured (q24 h, • ; q8 h, •) and predicted (q24 h, ; q8 h, ) drug concentrations in
the culture chamber, (b) The effect of both regimens (q24 h, ; q8 h, ) on the number of cfus
(geometric mean and range of duplicate experiments).
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Susceptibility to aminoglycosides was determined by a tube-dilution method in 2 ml
volumes containing inocula of 5 x 106 cfu/ml. MICs are listed in Table I. MBCs were
two- to fourfold higher than MICs for the strains of pseudomonas, and identical to the
MICs or twofold higher for the strains of serratia.
Results
All three aminoglycosides were rapidly and profoundly bactericidal in the in-vitro
models against sensitive and intermediately sensitive strains of P. aeruginosa and
S. marcescens (Tables I, II and Figure 3). Better initial bacterial killing was observed
with q24 h regimens compared to q8 h regimens (P < 001, Wilcoxon signed rank test).
For example, against P. aeruginosa ATCC 27853 the q24 h and q8 h regimens reduced
the inocula after 6 h by > 53 and 4-7 log10 for amikacin, > 5-3 and 3-6 log,0 for
isepamicin, and 3 and 1-8 log10 for netilmicin, respectively (means of duplicates; Model
G). However, regrowth occurred within 24 h in all experiments except for the q24 h
regimens with amikacin. These experiments were repeated in a model with a differently
designed growth chamber (model V; Figure 1). All three aminoglycosides showed
similar dose response in this model (Table II). The bactericidal effect was slightly
reduced (on an average by 0-8 log10) and all cultures regrew within 30 h.
Better bactericidal activity was observed with amikacin and isepamicin than with
netilimicin (Table I). This relates to the lower ratios of peak concentration to MIC
achieved with netilmicin. The MICs of the organisms studied were similar for all three
drugs, but three times lower doses of netilmicin were administered, to account for
differences in clinical dosing of these antibiotics.
Lower ratios of peak concentration to MIC were needed to achieve bactericidal
activity ( > 99-9% fold reduction of cfu) after 24 h of treatment against S. marcescens
compared to P. aeruginosa (P = 0011, Fisher's exact test, Table I). For S. marcescens a
peak/MIC ratio of > 4 occurred for nine of the 18 combinations of strain, drug and
dosing regimen and all of these nine combinations resulted in > 99-9% reduction in
viable bacteria. In contrast, for P. aeruginosa a peak/MIC ratio of ^ 4 only occurred
for six of the 18 combinations of strain, drug and dosing regimen. More importantly,
99-9% reduction in bacterial numbers only occurred in two out of these six combina-
tions. For example, despite identical ratios of amikacin peak concentration to MIC,
lower activity was found in the kinetic model against P. aeruginosa 14974 compared to
S. marcescens 77. Similarly, isepamicin was less active against P. aeruginosa A-10 than
against S. marcescens 76, despite identical peak to MIC ratios. Netilmicin also was less
active against P. aeruginosa 14974 than against S. marcescens 77 during exposure to
identical peak to MIC ratios. No bactericidal effect was observed after 24 h with
isepamicin against two strains of P. aeruginosa despite peaks of nine times the MIC.
However, isepamicin was bactericidal against serratia even at a peak to MIC ratio of
only 1-5.
Although better initial bacterial killing was observed with q24 h regimens compared
to q8 h regimens, comparable antibacterial efficacy was observed after 24 h during
most aminoglycoside treatments with both dosing regimens (Tables I, II). However, for
P. aeruginosa ATCC 27853 the q24 h regimen resulted in more rapid and complete
killing during the first 6 h of exposure (Figure 2). Moreover, there was no regrowth
despite the prolonged period with subinhibitory concentrations before the second dose,
whereas regrowth occurred during thrice-daily dosing (Figure 3, Table II). Similar
results were obtained with P. aeruginosa A-10 (Table I).
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Table II. Bactericidal effects of six aminoglycoside treatment regi-
mens after 6 and 24 h against P. aeruginosa (ATCC 27853). Inocula
of 2-8 x 106 cfu/ml were treated in two pharmacodynamic models
(Figures 1 and 2). Results are shown as cfu/ml 6 and 24 h after the
start of treatment
Drug and
timing of
effect
Amikacin
6 h
24 h
Isepamicin
6 h
24 h
Netilmicin
6 h
24 h
q8h
model V
lxlO 3
5x10'
2X103
6x10*
5X105
3x10'
regimen
model G
lxlO2
8x10*
lxlO3
2xlO7
lxlO5
7xlO6
q24h
model V
9x10'
1x10'
8x10'
6x10'
9XIO2
3x10'
regimen
model G
2x10'
<2xlO'
4X102
8x10'
7xlO2
3xlO7
Discussion
High peak to MIC ratios were required in both one-compartment in-vitro models to
achieve and maintain a bactericidal effect against P. aeruginosa over a treatment period
of 24 h or more. Similar results have been obtained previously in studies performed in a
capillary two-compartment model (Blaser et al, 1987). These data suggest insufficient
intrinsic activity of aminoglycosides for single drug treatment of high inocula of
P. aeruginosa in the absence of any host-defence mechanisms. In contrast, relatively
low peak to MIC ratios were sufficient to achieve and maintain a bactericidal effect
during in-vitro treatment of serratia.
In-vitro pharmacokinetic models simulate the treatment of infection in the absence
of host-defence mechanisms. During treatment of either Gram-negative or
Gram-positive bacteria resistant subpopulations emerge unless the peak to MIC ratio is
high enough to drastically reduce the bacterial inoculum within a few hours (Blaser et
al, 1985a). Similarly, rapid emergence of resistant subpopulations has been reported
during aminoglycoside treatment in neutropenic animals. Although the virulence and
clinical relevance of the relatively slow growing resistant subpopulations has been
documented both in animal and clinical studies (Gerber & Craig, 1982; Olson et al.,
1985), clinical experience suggests that this problem is more common in vitro than
during treatment of patients, particularly of non-neutropenic patients. This discrepancy
might relate to data suggesting enhanced activity of leucocytes against resistant
pathogens selected during antibiotic exposure (Schlaeffer et al., 1990). However,
treatment of infection in immunocompromised patients may still require antibiotic
suppression of regrowth of aminoglycoside-resistant subpopulations. Combination
therapy of an aminoglycoside plus a /Mactam antibiotic has been frequently used in this
situation (Hilf et al, 1989). Data obtained with in-vitro models of infection suggest
synergistic interactions due to prevention of the emergence of resistant subpopulations
by 0-lactams (Blaser et al, 19856).
Once-daily dosing was more bactericidal during the first 6 h of drug exposure and at
least as effective as thrice-daily dosing in preventing bacterial regrowth. The regimen of
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q24 h provides maximum peaks of eight times the MIC but the concentration falls
below the MIC within only 6 h (equivalent to three half-lives). Therefore subinhibitory
concentrations prevail during more than two-thirds of the dosing interval. These
observations suggest either complete sterilization of the system or a prolonged post-
antibiotic effect in the presence of subinhibitory concentrations before administration
of the next dose.
Data obtained in vitro support the concept of once-daily dosing of aminoglycosides
and suggest further clinical evaluations. Current clinical trials of optimal dosing of
aminoglycosides should provide information on the presence or absence of major
differenes in efficacy or toxicity. However, for statistical reasons large numbers of
patients will have to be enrolled in comparative studies to document differences in cure
rates. Ethical, practical and statistical limitations of clinical studies, emphasize the
importance of laboratory investigations in denning optimal dosing regimens.
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